OR5F1 Antibody

What is OR5F1 and why is it studied in research?

OR5F1 (Olfactory receptor family 5 subfamily F member 1) is a G protein-coupled receptor involved in olfactory signal transduction. Also known as Olfactory receptor 11-10 or OR11-10, this 35 kDa protein belongs to the olfactory receptor family that helps detect odor molecules and initiates neuronal responses . Research interest in OR5F1 stems from its role in olfaction mechanisms and potential involvement in non-olfactory tissues, where ectopic expression of olfactory receptors has been linked to various physiological and pathological processes. Studying OR5F1 requires specific antibodies that can reliably detect this protein in experimental systems.

What epitope regions are targeted by commercial OR5F1 antibodies?

Most commercial OR5F1 antibodies target specific amino acid sequences within the protein. For example, some polyclonal antibodies are generated against synthesized peptides derived from human OR5F1 at the amino acid range 265-314, which corresponds to the C-terminal region of the protein . This region was selected due to its unique sequence that distinguishes OR5F1 from other olfactory receptors, maximizing antibody specificity. When selecting an OR5F1 antibody for research, it's critical to evaluate which epitope is targeted, especially if studying receptor domains involved in ligand binding or protein-protein interactions.

How do polyclonal and monoclonal OR5F1 antibodies compare in research applications?

Polyclonal OR5F1 antibodies, such as those from Affinity Biosciences (DF5106) and Real-Gene Labs (4013063), recognize multiple epitopes on the OR5F1 protein, which can provide stronger signals but potentially lower specificity . These are beneficial for detection of low-abundance proteins or when protein conformation may be altered. In contrast, monoclonal antibodies like YP-mAb-13592 offer higher specificity to a single epitope, reducing cross-reactivity but potentially limiting detection if that epitope is masked or modified . For initial characterization studies, polyclonal antibodies may offer advantages in signal detection, while monoclonal antibodies are preferable for distinguishing OR5F1 from closely related olfactory receptors in comparative studies or when absolute specificity is required.

What are the recommended positive controls for validating OR5F1 antibody specificity?

When validating OR5F1 antibody specificity, researchers should use human cell lines known to express OR5F1, such as HeLa and Jurkat cells, which have been validated in western blot analyses as shown in published literature . A comprehensive validation should include: (1) A blocking experiment using the immunizing peptide, which should abolish the specific signal as demonstrated in western blot analyses where the lane blocked with synthesized peptide shows signal elimination ; (2) OR5F1-transfected cells compared with mock-transfected controls; and (3) Tissue samples with known expression patterns, particularly olfactory epithelium as a positive control and non-olfactory tissues as a specificity check. Additionally, using siRNA knockdown to reduce OR5F1 expression followed by antibody detection provides robust validation of specificity.

What are the optimal dilution ratios for different experimental applications?

Optimal dilution ratios vary by application and specific antibody preparation. For western blot applications, OR5F1 antibodies typically require dilutions between 1:500-1:2000, with many manufacturers recommending 1:500-1:1000 for optimal results . For immunofluorescence/immunocytochemistry (IF/ICC), a more concentrated preparation is generally needed, with recommended dilutions of 1:50-1:500, with 1:100-1:200 often providing the best signal-to-noise ratio . For ELISA applications, higher dilutions (1:5000) may be sufficient due to the higher sensitivity of the assay format . Researchers should always perform a dilution series during optimization, as factors such as target protein abundance, tissue type, fixation method, and detection system significantly influence optimal antibody concentration.

How should sample preparation be modified for detecting OR5F1 in different tissue types?

Sample preparation protocols should be tailored to the tissue type and experimental approach. For olfactory epithelium tissues, which naturally express OR5F1, mild fixation with 4% paraformaldehyde is recommended to preserve epitope accessibility. When working with neural tissues, adding protease inhibitors immediately after tissue collection is crucial to prevent degradation of the receptor. For western blot applications, membrane protein extraction buffers containing mild detergents (0.5-1% NP-40 or Triton X-100) are recommended to efficiently solubilize OR5F1 while maintaining its native conformation . When preparing cell lines such as HeLa or Jurkat for immunocytochemistry, using methanol/acetone fixation may provide better epitope exposure than aldehyde-based fixatives, especially when targeting the C-terminal region (AA 265-314) of OR5F1 .

How can researchers distinguish between specific OR5F1 signal and cross-reactivity?

Distinguishing specific OR5F1 signal from cross-reactivity requires multiple validation approaches. First, always run peptide blocking controls where the antibody is pre-incubated with the immunizing peptide before application to samples, which should eliminate specific binding as demonstrated in published western blot analyses . Second, verify that the detected protein appears at the expected molecular weight (35 kDa for OR5F1) . Third, compare your detection pattern across multiple antibodies targeting different epitopes of OR5F1 - true signal should be consistent across different antibodies. Finally, correlate protein detection with mRNA expression data from RT-PCR or RNA-seq. Discrepancies between these methods may indicate antibody cross-reactivity. For advanced validation, use CRISPR/Cas9 knockout models as negative controls, which provide definitive evidence of antibody specificity.

What causes weak or absent signal when using OR5F1 antibody in western blots?

Weak or absent signal in western blots can result from several factors. First, OR5F1 is a membrane protein and may require specialized extraction methods - standard RIPA buffers might not efficiently solubilize the protein. Using buffers with stronger detergents (1% SDS or 1% sodium deoxycholate) can improve extraction . Second, heating samples above 95°C can cause OR5F1 aggregation; limit heating to 70°C for 5 minutes. Third, transfer efficiency may be compromised for hydrophobic proteins; increasing transfer time or using specialized transfer systems for membrane proteins can help. Fourth, the epitope may be masked by post-translational modifications or protein interactions; try reducing sample complexity or using denaturing conditions. Finally, OR5F1 expression levels vary significantly across tissues and cell types, so ensure you're working with samples that express sufficient levels of the target protein.

How should researchers interpret multiple bands detected by OR5F1 antibody?

Multiple bands detected by OR5F1 antibody require careful interpretation. The expected molecular weight for OR5F1 is approximately 35 kDa , but additional bands may represent: (1) Post-translational modifications such as glycosylation, phosphorylation, or ubiquitination, which alter molecular weight; (2) Proteolytic fragments if sample preparation allowed degradation; (3) Oligomeric forms if sample denaturation was incomplete; or (4) Cross-reactivity with related olfactory receptors, particularly those in the OR5 family. To distinguish between these possibilities, researchers should: treat samples with glycosidases or phosphatases to remove modifications; improve sample preparation to minimize degradation; optimize denaturation conditions; and perform peptide competition assays to identify which bands represent specific binding. Additionally, comparing detection patterns across multiple OR5F1 antibodies targeting different epitopes can help identify which bands represent authentic OR5F1.

How can OR5F1 antibody be utilized in co-immunoprecipitation studies?

Utilizing OR5F1 antibody in co-immunoprecipitation (co-IP) studies requires special considerations due to OR5F1's membrane protein nature. First, select antibodies purified by affinity chromatography, such as those from Affinity Biosciences or Real-Gene Labs, which provide higher specificity for IP applications . Second, modify lysis conditions to preserve protein-protein interactions while efficiently extracting OR5F1 from membranes - typically using buffers containing 1% digitonin or 0.5% NP-40 supplemented with physiological salt concentrations (150mM NaCl). Third, pre-clear lysates with protein A/G beads to reduce non-specific binding. Fourth, consider cross-linking the antibody to beads using dimethyl pimelimidate to prevent antibody co-elution. For detection of novel interaction partners, perform parallel IPs with isotype control antibodies and OR5F1 antibodies blocked with immunizing peptide to identify non-specific interactions. Finally, validate potential interactions through reciprocal IPs and orthogonal methods like proximity ligation assays.

What adaptations are needed when using OR5F1 antibody for immunohistochemistry?

When adapting OR5F1 antibody for immunohistochemistry (IHC), several protocol modifications are essential. First, antigen retrieval is critical - for OR5F1, citrate buffer (pH 6.0) heated retrieval often yields better results than EDTA-based methods. Second, extend blocking time to at least 2 hours using 5-10% normal serum from the same species as the secondary antibody, supplemented with 0.3% Triton X-100 to enhance membrane permeabilization . Third, increase primary antibody incubation time to overnight at 4°C at dilutions of 1:50-1:200, which provides better signal penetration in tissue sections . Fourth, implement additional washing steps (6-8 washes of 10 minutes each) to reduce background. Fifth, use tyramide signal amplification systems to enhance detection sensitivity, particularly important for detecting low-abundance OR5F1 in non-olfactory tissues. Finally, include absorption controls where the antibody is pre-incubated with the immunizing peptide to validate signal specificity in tissue sections.

How effective is OR5F1 antibody for studying receptor trafficking in live cell imaging?

OR5F1 antibody has limitations for live cell imaging of receptor trafficking due to the membrane topology of olfactory receptors, which have extracellular N-termini but antibody epitopes often located in intracellular domains (like the C-terminal region AA 265-314) . For effective trafficking studies, researchers should consider these alternatives: (1) Generate fusion constructs with OR5F1 linked to fluorescent proteins like GFP or mCherry, positioning the tag to minimize interference with trafficking signals; (2) Use antibodies targeting extracellular epitopes of OR5F1 coupled with quantum dots or other non-permeating fluorophores for surface receptor tracking; (3) Develop cell-permeable antibody fragments or nanobodies that can access intracellular epitopes in live cells; or (4) Employ split-GFP complementation systems where one GFP fragment is fused to OR5F1 and the complementary fragment is targeted to specific cellular compartments, allowing visualization of receptor localization based on restored fluorescence. These approaches provide more reliable tracking of OR5F1 trafficking dynamics than conventional antibody staining.

How do polyclonal OR5F1 antibodies from different sources compare in specificity and sensitivity?

Polyclonal OR5F1 antibodies from different sources exhibit variable specificity and sensitivity profiles based on immunization strategies and purification methods. Antibodies from Affinity Biosciences (DF5106) and Real-Gene Labs (4013063) are purified using peptide affinity chromatography, which enhances specificity compared to whole serum preparations . Companies like Antibodypedia list multiple validated OR5F1 antibodies, with ABIN953882 having the strongest validation support (3 references) . Specificity can vary based on the exact immunizing sequence - antibodies targeting the C-terminal region (AA 265-314) generally show higher specificity than those targeting more conserved domains of the receptor . Sensitivity differences are apparent in western blot applications, where some antibodies detect endogenous OR5F1 in HeLa and Jurkat cells more effectively than others . When selecting between polyclonal antibodies, researchers should review validation data across multiple applications and consider epitope accessibility in their experimental system.

What are the advantages of using OR5F1 antibody versus genetic reporter systems?

OR5F1 antibody detection and genetic reporter systems each offer distinct advantages. Antibody-based detection allows visualization of endogenous OR5F1 without genetic manipulation, preserving native expression levels and regulatory mechanisms. This approach is particularly valuable for studies in primary tissues or when examining physiological regulation of OR5F1 . Additionally, antibodies can detect post-translational modifications through modification-specific antibodies, providing insights into receptor regulation that genetic reporters cannot capture. In contrast, genetic reporter systems (such as OR5F1-GFP fusions) offer advantages in live-cell imaging, enabling real-time tracking of receptor dynamics without fixation artifacts. They also provide higher specificity, eliminating cross-reactivity concerns, and can achieve higher sensitivity for low-expression scenarios. The ideal approach combines both methods: using genetic reporters for live dynamics and antibody detection to validate findings in endogenous systems and to examine post-translational modifications.

How can researchers validate OR5F1 antibody performance across species?

Validating OR5F1 antibody performance across species requires systematic cross-species reactivity testing. Most commercial OR5F1 antibodies are specifically raised against human sequences, though some also report reactivity with rat and mouse OR5F1 . For cross-species validation, researchers should: (1) Perform sequence alignment analysis of the antibody's target epitope across species to predict potential cross-reactivity; (2) Test antibody performance in western blots using tissue lysates from each species of interest, comparing olfactory epithelium samples where OR5F1 should be expressed; (3) Include blocking peptide controls for each species to confirm signal specificity; (4) Validate positive signals with orthogonal methods such as RT-PCR or RNA-seq data for the corresponding species; and (5) Consider using evolutionarily conserved epitopes when designing new antibodies for multi-species studies. For the OR5F1 antibody shown to react with human, mouse, and rat samples, researchers should still perform validation in their specific experimental conditions, as cross-reactivity can vary depending on antibody lot and experimental parameters .